Pricing Log in Create free account

Cingulate Inc. (CING) vs Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Cingulate Inc. and Corbus Pharmaceuticals Holdings, Inc. are both Biotechnology companies. Cingulate Inc. is the larger, with a market value of $61.7M against $55.3M — 1.1× the size. Across the 8 metrics below, Cingulate Inc. leads on 4 and Corbus Pharmaceuticals Holdings, Inc. on 4.

Valuation

Metric CING CRBP Biotechnology median
P/E n/m n/m 10.60
P/S n/m 38.44 9.40
P/B 2.39 0.58 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.34 0.66
EV/Sales n/m (23.77) 9.02
Earnings yield (86.36%) (202.95%) (32.88%)
Free cash flow yield (37.28%) (146.45%) (23.13%)

Profitability

Metric CING CRBP Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (198.74%) (95.58%) (51.96%)
Return on assets (123.76%) (80.85%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CING CRBP Biotechnology median
Revenue growth (TTM) — (73.69%) 6.76%
EPS growth (last fiscal year) 59.12% (60.33%) 29.88%
Revenue growth, 5-year CAGR — (14.34%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CING CRBP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.50 5.71 4.97
Net debt to EBITDA 0.51 1.90 1.01

Dividend

Metric CING CRBP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CING CRBP Biotechnology median
Market cap 61.66m 55.32m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack